NEW YORK (GenomeWeb News) - Canadian biomarker developer Med BioGene has hired an investment advisory and financial services company and has granted some of its executives options to buy up to 560,000 common shares at Can$.34 ($.32) a share, the company said today.
 
The Vancouver, BC-based MBI said it has hired Peterson Capital, an investment, financial services, and communications firm, for a monthly cash rate and the option to buy up to 100,000 shares at Can$.34 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.